In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Factory Mutual Insurance Co. dramatically upped its stake in Regeneron Pharmaceuticals by 210.3%, acquiring an additional ...

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Regeneron Pharma stock has been in a persistent downtrend for over 280 days. Here's why you should avoid REGN.

Regeneron Pharmaceuticals just got a haircut from Wall Street, with JPMorgan Chase & Co. lowering its price target from $950 ...

Shares of biotech company Regeneron (NASDAQ:REGN) fell 19% in the afternoon session after the company announced mixed results ...

Much of this decline can be attributed to the company ... Given the substantial fall in Regeneron’s stock price, the natural question arises: is REGN now an attractive buying opportunity?

The company’s stock, currently trading at $529.24 ... Eylea has been a significant revenue driver for Regeneron, and its decline poses a substantial risk to the company’s financial performance.

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

10.4% decline over the past year and 6.5% fall on a YTD basis. Regeneron stock tumbled 6.9% following the release of its weaker-than-expected Q1 2025 results on Apr. 29. The company reported ...